COVID-19: A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD CROSSOVER STUDY TO ESTIMATE THE EFFECT OF ITRACONAZOLE ON THE PHARMACOKINETICS OF PF-07321332/RITONAVIR IN HEALTHY PARTICIPANTS
Latest Information Update: 17 Jul 2023
At a glance
- Drugs Itraconazole (Primary) ; Nirmatrelvir+ritonavir (Primary) ; Ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Pharmacokinetics
- Sponsors Pfizer
- 11 Oct 2021 Status changed from recruiting to completed.
- 29 Jul 2021 Status changed from not yet recruiting to recruiting.
- 26 Jul 2021 Planned End Date changed from 18 Oct 2021 to 1 Oct 2021.